作为一种替代选择,用于胺胺耐药的格雷夫斯病
Ying Ki Chung1, Lap Ming Wong2
1Department of Paediatrics and Adolescent Medicine, Caritas Medical Centre, Kowloon, Hong Kong, China.
概括
这个案例研究表明,可以有效地管理Graves.
科学领域:
- 内分泌学和新陈代谢学
- 甲状腺学 甲状腺学
背景情况:
- 格雷夫斯病是一种自身免疫性疾病,导致甲状腺功能过高.
- 标准治疗包括硫胺胺,放射性治疗 (RAI) 和甲状腺切除术.
- 胺胺耐药性需要使用替代管理策略.
研究的目的:
- 在青少年中呈现一种对硫胺胺耐药格雷夫斯病的病例.
- 在确定治疗之前评估在治疗甲状腺功能障碍的有效性.
主要方法:
- 一个案例报告,一个青春期的女性患有抗 thionamide 的格雷夫斯病.
- 治疗包括使用来稳定甲状腺激素水平.
- 随后进行放射性治疗 (RAI).
主要成果:
- 成功控制了甲状腺功能障碍,使得RAI的准备成为可能.
- 患者通过获得了稳定的甲状腺激素水平.
- 在RAI之后,甲状腺功能低下症发展,用甲状腺素替代物治疗.
结论:
- 提供了一种安全有效的选择,用于管理耐火格雷夫斯病的甲状腺功能障碍.
- 可以作为一种有价值的辅助剂,用于为患者准备RAI等最终疗法.
- 这种方法可以改善挑战格雷夫斯病病例的结果.
相关概念视频
Mania and Antimanic Drugs: Overview
253
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
253
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.1K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.1K
Antiepileptic Drugs: Glutamate Antagonists
429
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
429
Electroconvulsive Therapy
75
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
75
Myasthenia Gravis: Overview and Treatment
1.6K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
351
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
351


